Reductive carboxylation supports growth in tumour cells with defective mitochondria
- PMID: 22101431
- PMCID: PMC3262117
- DOI: 10.1038/nature10642
Reductive carboxylation supports growth in tumour cells with defective mitochondria
Abstract
Mitochondrial metabolism provides precursors to build macromolecules in growing cancer cells. In normally functioning tumour cell mitochondria, oxidative metabolism of glucose- and glutamine-derived carbon produces citrate and acetyl-coenzyme A for lipid synthesis, which is required for tumorigenesis. Yet some tumours harbour mutations in the citric acid cycle (CAC) or electron transport chain (ETC) that disable normal oxidative mitochondrial function, and it is unknown how cells from such tumours generate precursors for macromolecular synthesis. Here we show that tumour cells with defective mitochondria use glutamine-dependent reductive carboxylation rather than oxidative metabolism as the major pathway of citrate formation. This pathway uses mitochondrial and cytosolic isoforms of NADP(+)/NADPH-dependent isocitrate dehydrogenase, and subsequent metabolism of glutamine-derived citrate provides both the acetyl-coenzyme A for lipid synthesis and the four-carbon intermediates needed to produce the remaining CAC metabolites and related macromolecular precursors. This reductive, glutamine-dependent pathway is the dominant mode of metabolism in rapidly growing malignant cells containing mutations in complex I or complex III of the ETC, in patient-derived renal carcinoma cells with mutations in fumarate hydratase, and in cells with normal mitochondria subjected to acute pharmacological ETC inhibition. Our findings reveal the novel induction of a versatile glutamine-dependent pathway that reverses many of the reactions of the canonical CAC, supports tumour cell growth, and explains how cells generate pools of CAC intermediates in the face of impaired mitochondrial metabolism.
Conflict of interest statement
None of the authors have competing financial interests to declare. Reprints and permissions information is available at
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3262117/bin/nihms331574f1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3262117/bin/nihms331574f2.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3262117/bin/nihms331574f3.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3262117/bin/nihms331574f4.gif)
Similar articles
-
Reductive carboxylation supports redox homeostasis during anchorage-independent growth.Nature. 2016 Apr 14;532(7598):255-8. doi: 10.1038/nature17393. Epub 2016 Apr 6. Nature. 2016. PMID: 27049945 Free PMC article.
-
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia.Nature. 2011 Nov 20;481(7381):380-4. doi: 10.1038/nature10602. Nature. 2011. PMID: 22101433 Free PMC article.
-
Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability.Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19611-6. doi: 10.1073/pnas.1117773108. Epub 2011 Nov 21. Proc Natl Acad Sci U S A. 2011. PMID: 22106302 Free PMC article.
-
Metabolic and mind shifts: from glucose to glutamine and acetate addictions in cancer.Curr Opin Clin Nutr Metab Care. 2015 Jul;18(4):346-53. doi: 10.1097/MCO.0000000000000178. Curr Opin Clin Nutr Metab Care. 2015. PMID: 26001655 Review.
-
Mitochondrial dysfunctions in cancer: genetic defects and oncogenic signaling impinging on TCA cycle activity.Cancer Lett. 2015 Jan 28;356(2 Pt A):217-23. doi: 10.1016/j.canlet.2014.02.023. Epub 2014 Mar 12. Cancer Lett. 2015. PMID: 24614286 Review.
Cited by
-
13C metabolite tracing reveals glutamine and acetate as critical in vivo fuels for CD8 T cells.Sci Adv. 2024 May 31;10(22):eadj1431. doi: 10.1126/sciadv.adj1431. Epub 2024 May 29. Sci Adv. 2024. PMID: 38809979 Free PMC article.
-
AGC1-mediated Metabolic Reprogramming and Autophagy Sustain Survival of Hepatocellular Carcinoma Cells under Glutamine Deprivation.Cell Biochem Biophys. 2024 May 24. doi: 10.1007/s12013-024-01311-y. Online ahead of print. Cell Biochem Biophys. 2024. PMID: 38789662
-
Targeting Mitochondria for Cancer Treatment.Pharmaceutics. 2024 Mar 23;16(4):444. doi: 10.3390/pharmaceutics16040444. Pharmaceutics. 2024. PMID: 38675106 Free PMC article. Review.
-
Wild-type IDH2 is a therapeutic target for triple-negative breast cancer.Nat Commun. 2024 Apr 24;15(1):3445. doi: 10.1038/s41467-024-47536-6. Nat Commun. 2024. PMID: 38658533 Free PMC article.
-
Glutaminolysis regulates endometrial fibrosis in intrauterine adhesion via modulating mitochondrial function.Biol Res. 2024 Apr 1;57(1):13. doi: 10.1186/s40659-024-00492-3. Biol Res. 2024. PMID: 38561846 Free PMC article.
References
-
- Baysal BE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287:848–851. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K01 DK078933-03/DK/NIDDK NIH HHS/United States
- K08 DK072565/DK/NIDDK NIH HHS/United States
- T32 CA009560/CA/NCI NIH HHS/United States
- T32CA009560/CA/NCI NIH HHS/United States
- T32 GM083831-04/GM/NIGMS NIH HHS/United States
- DK078933/DK/NIDDK NIH HHS/United States
- T32 GM008061/GM/NIGMS NIH HHS/United States
- T32 GM083831/GM/NIGMS NIH HHS/United States
- R01CA123067/CA/NCI NIH HHS/United States
- K08DK072565/DK/NIDDK NIH HHS/United States
- 5T32GM083831/GM/NIGMS NIH HHS/United States
- P41 RR002584-22/RR/NCRR NIH HHS/United States
- P41 RR002584/RR/NCRR NIH HHS/United States
- R01 CA157996/CA/NCI NIH HHS/United States
- R01CA157996/CA/NCI NIH HHS/United States
- T32GM008061/GM/NIGMS NIH HHS/United States
- T32 GM008061-30/GM/NIGMS NIH HHS/United States
- R01 CA123067/CA/NCI NIH HHS/United States
- R01 CA123067-05/CA/NCI NIH HHS/United States
- ImNIH/Intramural NIH HHS/United States
- K08 DK072565-06/DK/NIDDK NIH HHS/United States
- RR02584/RR/NCRR NIH HHS/United States
- T32 CA009560-20/CA/NCI NIH HHS/United States
- R01 CA157996-01/CA/NCI NIH HHS/United States
- K01 DK078933/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous